Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Nov 2019 Results of pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine, using blood concentration data from 1,162 of 1,686 patients who had participated in either of two previously completed Phase 3 trials (TRx-237-015 and TRx-237-005) presented in a TauRx Therapeutics media release.
26 Nov 2019 According to a TauRx Therapeutics media release, results from 1,162 patients who had participated in either of two previously completed Phase 3 trials that assessed the pharmacological activity were published in Journal of Alzheimers Disease
26 Nov 2019 Results of pharmacokinetic analyses (n=1162) published in the Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com